Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)-Reference-Cited by-同舟云学术

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

Published:2014-08-07 Issue:10 Volume:21 Page:3261-3267
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Whitworth Pat,Stork-Sloots Lisette,de Snoo Femke A.,Richards Paul,Rotkis Michael,Beatty Jennifer,Mislowsky Angela,Pellicane James V.,Nguyen Bichlien,Lee Laura,Nash Charles,Gittleman Mark,Akbari Stephanie,Beitsch Peter D.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/article/10.1245/s10434-014-3908-y/fulltext.html

Reference11 articles.

1. Krijgsman O, Roepman P, Zwart W, et al. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat. 2012;133:37–47.

2. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.

3. Gluck S, De Snoo F, Peeters J, Stork-Sloots L, Somlo G. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neo-adjuvant chemotherapy. Breast Cancer Res Treat. 2013;139(3):759–67.

4. Viale G, Slaets L, de Snoo F, et al. Pathological assessment of discordant cases for molecular (BluePrint and MammaPrint) versus clinical subtypes for breast cancer among 621 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial. Cancer Res. 2012;72(24 Suppl):303s.

5. Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010;6(4):195–7.

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathologic Complete Response to Neoadjuvant Chemotherapy and Pembrolizumab in Postpartum High-Risk Basal-Type Breast Cancer;Cureus;2024-06-13

2. Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial;JCO Precision Oncology;2024-02

3. Molecular testing in breast cancer;Diagnostic Molecular Pathology;2024

4. First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial;Journal for ImmunoTherapy of Cancer;2023-12

5. Optimising of axillary therapy in breast cancer: lessons from the past to plan for a better future;La radiologia medica;2023-11-03